Overview

PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)

Status:
Completed
Trial end date:
2019-11-15
Target enrollment:
Participant gender:
Summary
This study has been designed as a multicentre, randomised, open label study of AVT02 in healthy adult subjects. The study will assess the PK, safety and tolerability of AVT02 in Pre-Filled Syringe compared to AVT02 in Autoinjector Pen. Both arms will use single dose of 40mg of AVT02 (Adalimumab)
Phase:
Phase 1
Details
Lead Sponsor:
Alvotech Swiss AG
Treatments:
Adalimumab